PE20020351A1 - Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2 - Google Patents
Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2Info
- Publication number
- PE20020351A1 PE20020351A1 PE2001000900A PE2001000900A PE20020351A1 PE 20020351 A1 PE20020351 A1 PE 20020351A1 PE 2001000900 A PE2001000900 A PE 2001000900A PE 2001000900 A PE2001000900 A PE 2001000900A PE 20020351 A1 PE20020351 A1 PE 20020351A1
- Authority
- PE
- Peru
- Prior art keywords
- chloro
- methyl
- fluoroaniline
- phenylacetic acid
- cyclooxygenase
- Prior art date
Links
- 102000010907 Cyclooxygenase 2 Human genes 0.000 title abstract 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 229960001021 lactose monohydrate Drugs 0.000 abstract 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 239000004408 titanium dioxide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23165500P | 2000-09-11 | 2000-09-11 | |
| US23226100P | 2000-09-14 | 2000-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020351A1 true PE20020351A1 (es) | 2002-06-14 |
Family
ID=26925315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000900A PE20020351A1 (es) | 2000-09-11 | 2001-09-07 | Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20020061932A1 (enExample) |
| EP (1) | EP1331972B1 (enExample) |
| JP (2) | JP2004527458A (enExample) |
| KR (1) | KR20030036730A (enExample) |
| CN (1) | CN100490797C (enExample) |
| AR (1) | AR030630A1 (enExample) |
| AT (1) | ATE366128T1 (enExample) |
| AU (2) | AU2002213900C1 (enExample) |
| BR (1) | BR0113809A (enExample) |
| CA (1) | CA2416771C (enExample) |
| CY (1) | CY1107729T1 (enExample) |
| CZ (1) | CZ2003673A3 (enExample) |
| DE (1) | DE60129238T2 (enExample) |
| DK (1) | DK1331972T3 (enExample) |
| ES (1) | ES2290181T3 (enExample) |
| HU (1) | HUP0301128A3 (enExample) |
| IL (2) | IL154238A0 (enExample) |
| MX (1) | MXPA03002105A (enExample) |
| MY (1) | MY126117A (enExample) |
| NO (1) | NO20031095D0 (enExample) |
| NZ (1) | NZ524785A (enExample) |
| PE (1) | PE20020351A1 (enExample) |
| PL (1) | PL359721A1 (enExample) |
| PT (1) | PT1331972E (enExample) |
| RU (1) | RU2316324C2 (enExample) |
| SI (1) | SI1331972T1 (enExample) |
| SK (1) | SK2902003A3 (enExample) |
| WO (1) | WO2002020090A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036312A1 (es) * | 2001-08-31 | 2004-08-25 | Novartis Ag | Composicion farmaceutica |
| GB0201520D0 (en) * | 2002-01-23 | 2002-03-13 | Novartis Ag | Pharmaceutical uses |
| CA2476744A1 (en) * | 2002-03-07 | 2003-09-12 | Novartis Ag | Solid pharmaceutical compositions comprising lumiracoxib |
| US7220749B2 (en) | 2002-06-11 | 2007-05-22 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| AR042206A1 (es) | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
| TWI327913B (en) * | 2003-03-12 | 2010-08-01 | Novartis Ag | Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid |
| US20050131028A1 (en) * | 2003-09-11 | 2005-06-16 | Pharmacia Corporation | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders |
| RU2423979C2 (ru) * | 2005-06-17 | 2011-07-20 | АФТ Фармасьютикалз Лимитед | Новая фармацевтическая композиция и ее применение в способе лечения пациентов с гиперемией и отеком слизистой оболочки верхних дыхательных путей |
| FR2898492B1 (fr) * | 2006-03-15 | 2008-06-06 | Pierre Fabre Medicament Sa | Comprimes orodispersibles de domperidone |
| US20080014228A1 (en) * | 2006-07-14 | 2008-01-17 | Olivia Darmuzey | Solid form |
| WO2008086537A2 (en) * | 2007-01-11 | 2008-07-17 | Analog Devices, Inc. | Aluminum based bonding of semiconductor wafers |
| AU2009282901A1 (en) * | 2008-08-22 | 2010-02-25 | Novartis Ag | Use of a COX-2 inhibitor for the treatment of a COX-2 dependent disorder in a patient not carrying HLA alleles associated with hepatotoxicity |
| US8227451B2 (en) | 2008-11-12 | 2012-07-24 | Auspex Pharmaceuticals | Phenylacetic acid inhibitors of cyclooxygenase |
| CN103773596B (zh) * | 2013-12-31 | 2016-05-18 | 上海复力生物医药科技有限公司 | 磷虾油的制备方法 |
| KR102557900B1 (ko) | 2016-09-07 | 2023-07-19 | 트러스티즈 오브 터프츠 칼리지 | 면역-dash 억제제와 pge2 길항제를 이용한 병행 요법 |
| EP3687505A1 (en) | 2017-09-26 | 2020-08-05 | Tesaro Inc. | Niraparib formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0701449T3 (da) * | 1993-06-08 | 2003-11-10 | Novartis Ag | Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac |
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| EP0910368A1 (en) * | 1996-05-17 | 1999-04-28 | Merck & Co., Inc. | Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases |
| CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| AR036312A1 (es) * | 2001-08-31 | 2004-08-25 | Novartis Ag | Composicion farmaceutica |
-
2001
- 2001-09-07 PE PE2001000900A patent/PE20020351A1/es not_active Application Discontinuation
- 2001-09-07 AR ARP010104260A patent/AR030630A1/es unknown
- 2001-09-10 CA CA2416771A patent/CA2416771C/en not_active Expired - Fee Related
- 2001-09-10 MY MYPI20014237A patent/MY126117A/en unknown
- 2001-09-10 AU AU2002213900A patent/AU2002213900C1/en not_active Ceased
- 2001-09-10 DE DE60129238T patent/DE60129238T2/de not_active Expired - Lifetime
- 2001-09-10 PL PL35972101A patent/PL359721A1/xx not_active Application Discontinuation
- 2001-09-10 DK DK01982270T patent/DK1331972T3/da active
- 2001-09-10 NZ NZ524785A patent/NZ524785A/en unknown
- 2001-09-10 RU RU2003109606/15A patent/RU2316324C2/ru not_active IP Right Cessation
- 2001-09-10 ES ES01982270T patent/ES2290181T3/es not_active Expired - Lifetime
- 2001-09-10 WO PCT/EP2001/010448 patent/WO2002020090A2/en not_active Ceased
- 2001-09-10 PT PT01982270T patent/PT1331972E/pt unknown
- 2001-09-10 HU HU0301128A patent/HUP0301128A3/hu unknown
- 2001-09-10 SK SK290-2003A patent/SK2902003A3/sk unknown
- 2001-09-10 EP EP01982270A patent/EP1331972B1/en not_active Expired - Lifetime
- 2001-09-10 BR BR0113809-0A patent/BR0113809A/pt not_active Application Discontinuation
- 2001-09-10 AT AT01982270T patent/ATE366128T1/de active
- 2001-09-10 KR KR10-2003-7002711A patent/KR20030036730A/ko not_active Ceased
- 2001-09-10 CZ CZ2003673A patent/CZ2003673A3/cs unknown
- 2001-09-10 MX MXPA03002105A patent/MXPA03002105A/es active IP Right Grant
- 2001-09-10 SI SI200130773T patent/SI1331972T1/sl unknown
- 2001-09-10 IL IL15423801A patent/IL154238A0/xx active IP Right Grant
- 2001-09-10 JP JP2002524572A patent/JP2004527458A/ja not_active Withdrawn
- 2001-09-10 AU AU1390002A patent/AU1390002A/xx active Pending
- 2001-09-10 CN CNB018154549A patent/CN100490797C/zh not_active Expired - Fee Related
- 2001-09-11 US US09/950,538 patent/US20020061932A1/en not_active Abandoned
-
2003
- 2003-01-30 IL IL154238A patent/IL154238A/en not_active IP Right Cessation
- 2003-03-10 NO NO20031095A patent/NO20031095D0/no not_active Application Discontinuation
-
2004
- 2004-03-24 US US10/807,734 patent/US20040186179A1/en not_active Abandoned
-
2007
- 2007-09-07 CY CY20071101157T patent/CY1107729T1/el unknown
-
2011
- 2011-03-09 JP JP2011051754A patent/JP2011144194A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020351A1 (es) | Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2 | |
| ES2244831T5 (es) | Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica | |
| PE20130210A1 (es) | Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph | |
| BR9611015A (pt) | Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto | |
| HRP20050663A2 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
| UY29919A1 (es) | Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones | |
| MA31706B1 (fr) | Formulations galéniques de composés organiques | |
| NZ584686A (en) | Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate | |
| UY30274A1 (es) | Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones | |
| AR079404A1 (es) | Antagonista dp2 y composicion farmaceutica, uso y proceso de preparacion | |
| CR9721A (es) | Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos | |
| MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
| CO5560554A2 (es) | Composicion farmaceutica que comprende lumiracoxib | |
| NZ592647A (en) | Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester | |
| EP2196206A4 (en) | MEDICAMENT FOR TREATING SKIN PROBLEMS WITH A MORPHINE DERIVATIVE OR PHARMACOLOGICALLY COMPATIBLE ACIDIC ACID SALT AS AN ACTIVE SUBSTANCE | |
| PA8426801A1 (es) | Composiciones farmaceuticas para el tratamiento de la rinitis. | |
| CO5011084A1 (es) | Composiciones y metodos para tratar trastornos respiratorios | |
| BRPI0413186A (pt) | composição de fexofenadina e processo para preparação da mesma | |
| WO2008026048A3 (en) | Stable injectable pharmaceutical compositions of docetaxel | |
| PE20250835A1 (es) | Composiciones y uso de la tirzepatida | |
| ES2191099T3 (es) | Derivados de hidantoina como productos intermedios para principios activos farmaceuticos. | |
| TR199701497T1 (xx) | Beyin �demini �nleyen terkip. | |
| DK2069334T3 (da) | Aspalathin-lignende dihydrochalcon, ekstrakter af ufermenteret rooibos og fremgangsmåde til fremstilling | |
| AR044014A1 (es) | Composiciones farmaceuticas para administracion intranasal de acido [2-(8,9-dioxo-2, 6-diazabiciclo [5.2.0) non-1 (7) -en-2-il)alquil]-fosfonico y derivados y metodos de utilizacion de las mismas | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |